Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. 1979

G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D006952 Hyperlipoproteinemia Type III An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides. Autosomal Recessive Hypercholesterolemia,Broad Beta Disease,Dysbetalipoproteinemia,Dysbetalipoproteinemia, Familial,Familial Dysbetalipoproteinemia,Familial Hypercholesterolemia with Hyperlipemia,Hypercholesterolemia, Autosomal Recessive,Hyperlipoproteinemia, Broad-beta,Hyperlipoproteinemia, Type III,Autosomal Recessive Hypercholesterolemias,Broad-beta Hyperlipoproteinemia,Hyperlipoproteinemia, Broad beta,Hyperlipoproteinemias, Type III,Recessive Hypercholesterolemia, Autosomal,Type III Hyperlipoproteinemia,Type III Hyperlipoproteinemias
D006953 Hyperlipoproteinemia Type IV A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits. Hyperprebetalipoproteinemia,Hypertriglyceridemia, Familial,Carbohydrate Inducible Hyperlipemia,Carbohydrate-Inducible Hyperlipemia,Familial Hyperlipoproteinemia Type 4,Familial Type IV Hyperlipoproteinemia,Hyper prebeta lipoproteinemia,Hyperlipoproteinemia, Type IV,Carbohydrate Inducible Hyperlipemias,Carbohydrate-Inducible Hyperlipemias,Familial Hypertriglyceridemia,Hyperlipemia, Carbohydrate Inducible,Hyperlipemia, Carbohydrate-Inducible,Hyperlipemias, Carbohydrate Inducible,Hyperlipemias, Carbohydrate-Inducible,Hyperlipoproteinemias, Type IV,Inducible Hyperlipemia, Carbohydrate,Inducible Hyperlipemias, Carbohydrate,Type IV Hyperlipoproteinemia,Type IV Hyperlipoproteinemias,Type IV, Hyperlipoproteinemia
D006954 Hyperlipoproteinemia Type V A severe type of hyperlipidemia, sometimes familial, that is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I . Hyperchylomicronemia Late Onset,Hyperchylomicronemia With Hyperprebetalipoproteinemia, Familial,Hyperchylomicronemia, Late-Onset,Hyperlipemia, Combined Fat And Carbohydrate-Induced,Hyperlipemia, Mixed,Hyperlipidemia, Type V,Hyperlipoproteinemia Type 5,Hyperlipoproteinemia, Type V,Hyperchylomicronemia Late Onsets,Hyperchylomicronemia, Late Onset,Hyperchylomicronemias, Late-Onset,Hyperlipemia, Combined Fat And Carbohydrate Induced,Hyperlipemias, Mixed,Hyperlipidemias, Type V,Hyperlipoproteinemia Type 5s,Hyperlipoproteinemias, Type V,Late-Onset Hyperchylomicronemia,Late-Onset Hyperchylomicronemias,Mixed Hyperlipemia,Mixed Hyperlipemias,Type V Hyperlipidemia,Type V Hyperlipidemias,Type V Hyperlipoproteinemia,Type V Hyperlipoproteinemias
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol

Related Publications

G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
January 1979, Clinical genetics,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
February 1984, Gastroenterologia Japonica,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
December 2004, Nihon rinsho. Japanese journal of clinical medicine,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
September 1979, Atherosclerosis,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
January 1998, Ryoikibetsu shokogun shirizu,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
September 2006, Clinical biochemistry,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
December 1981, Science (New York, N.Y.),
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
November 1976, Metabolism: clinical and experimental,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
February 2006, Rinsho byori. The Japanese journal of clinical pathology,
G Schonfeld, and P K George, and J Miller, and P Reilly, and J Witztum
January 2020, Science translational medicine,
Copied contents to your clipboard!